7
A P P L I C A T I O N N O T E
Dianthus ensures that researchers can accurately and cost-effectively assess cooperativity, even
in complex drug discover y programs. Hans-Jörg's experience highlights how this innovative
technology is essential in the development of next-generation proximity inducers, optimizing
their efficacy while minimizing off-target effects.
CONCLUSION
As proximity-inducing therapies like PROTACs and molecular glues continue to show
promise in the modulation of difficult targets, optimizing cooperativity remains
a pivotal challenge. Hans-Jörg emphasizes that the future of proximity-inducing
therapies relies on the ability to design small molecules that maximize cooperativity,
allowing for lower molecular weights and greater specificity. Dianthus addresses
these challenges by offering a sophisticated screening platform that helps researchers
identify molecular glues, optimize cooperativity, and refine the development of
proximity-inducing drugs.
Dianthus is a powerful tool to accelerate the identification and characterization of
next-generation proximity-inducers. Dianthus paves the way for the creation of more
effective, safe, and specific therapies. The future of proximity-based drugs is bright,
and Dianthus stands at the forefront of this exciting evolution.
3
In October 2024, NanoTemper Technologies introduced the Dianthus uHTS, the fastest biophysical affinity measurement
instrument currently available. Dianthus uHTS significantly enhances throughput by utilizing NanoTemper 's proprietar y
Spectral Shift technology, enabling the measurement of a full 1536-well plate in under 8 minutes.
U S E R C A S E S T U D Y
